What question did this study set out to answer?

This meta-analysis examines severe and immune-related toxicities associated with dual checkpoint blockade in melanoma brain metastases.

November 1, 2025Neuro-OncologyOpen Access

Ctim-29. Toxicity Profile of Dual Immune Checkpoint Blockade in Melanoma Brain Metastases: A Meta-Analysis of Grade ≥3 and Immune-Related Adverse Events

View Full Paper

Ask AI

Bookmark

This meta-analysis examines severe and immune-related toxicities associated with dual checkpoint blockade in melanoma brain metastases.
Systematically searched multiple databases through March 2025 for eligible studies.
Assessed high-grade adverse events and immune-related adverse events based on study-defined criteria.
Pooled proportions and confidence intervals were estimated using random-effects meta-analysis.
Included 18 studies encompassing 1,391 patients with melanoma brain metastases.
Pooled incidence of Grade ≥3 adverse events was 47%; immune-related adverse events were 63%.
High variability in adverse event incidence across studies was noted.

No takes yet. Share an insight, caveat, or question.

Meta-analysis reveals high incidence of immune-related adverse events in melanoma brain metastases, suggesting need for better monitoring protocols.

Sarfraz et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Meta-analysis reveals high incidence of immune-related adverse events in melanoma brain metastases, suggesting need for better monitoring protocols.